What top creators are saying about Sarepta Therapeutics, Inc.(SRPT)

Viewed as a value stock with a valuation floor near revenue/asset levels; long-term gene therapy data for Elevidys looks promising.

The speaker's sentiment shifted from initially negative to cautiously bullish, noting the stock is 'bottoming out pretty well,' suggesting a potential turnaround or that the stock has found a floor.

Briefly mentioned with a continued bullish sentiment, with the speaker stating he 'still like[s] them'.

Noted for having been 'weak in momentum for about six months,' indicating a bearish or cautious stance on the stock's recent performance.

The speaker has a highly contradictory view, at times seeing it as a beaten-down recovery play that could reach $50, while at other times stating they are actively shorting it.

The speaker is 'over the moon about' this stock, making it a high-conviction bullish pick.

Bullish, as the speaker confirms he is 'still in' the stock, indicating a continuing long position.

The speaker is long the stock with a generally positive tone, but is also actively trading it by selling shares on bounces, suggesting a bullish but risk-managed approach.

Speaker had a successful long trade on the stock's 'huge bounce' and 'real nice recovery.' They have taken partial profits but still hold a position.

The speaker is frustrated with the investment's poor performance and highlights significant risks, including internal FDA politics. They advise extreme caution, suggesting it is a highly speculative and difficult area to invest in.

The speaker maintains a continued bullish stance, confirming they are 'still in Sarepta' and have not changed their positive view on the company.

A straightforward bullish endorsement, with the speaker stating directly, 'I like Sarepta. Sarepta is my stock.'

The speaker is long the stock and has a price target of $50.

The speaker is bullish and has taken a long position with both shares and call options, citing an attractive low valuation ('one or two times sales') as a key reason.

The speaker expressed a very bullish view, suggesting significant upside with the comment 'Sarepta's going to like 50, man. I should just stop shorting quantum and buy calls on Sarepta.'

The speaker is bullish for the long term, viewing it as a turnaround play. The company is currently out of favor with Wall Street, which could present a buying opportunity for patient investors.

Presented as a 'long' idea due to recent three-year clinical data that 'looks pretty good' and was presented at the World Muscle Society.

The speaker is bullish, stating he 'still likes' the stock and believes it 'should be able to get $50 pretty easily.'

The speaker gives a clear, bullish endorsement, stating the stock 'has done really well. I like Sarepta.'

The speaker expressed a very bullish view, stating the stock is 'definitely looking nice' and suggested a potential price target of $40 or $50, which it could reach 'pretty easily'.

The speaker holds a position and expresses a very positive sentiment, stating the company is 'just too much too good to ignore,' suggesting significant value or a strong catalyst.

The host is bullish, stating 'I do think syrup that will run' based on positive diligence about the demand for its treatment, Elevidys.

The speaker explicitly stated, 'I bought some Sarepta' and confirmed he is bullish on the company.

Mentioned as a stock that was a great buy in the past during a panic. Now that it has recovered, the speaker implies the best opportunity may be over for now.

Upcoming data for its limb-girdle muscular dystrophy (LGMD) drug is a major potential catalyst that could 'double the stock or get us up to $30'.

Listed as one of the speaker's biggest long positions. It is presented as a long-term bullish investment that will be a 'journey' and not a 'get rich quick' stock. The speaker might trim the position after a recent run-up.

The speaker is currently bullish and holds a large position (14% of portfolio) after successfully trading the volatility. He employed a 'crisis investing' strategy, buying heavily after bad news, demonstrating high conviction in the company's long-term value.

Bullish sentiment based on high, long-term conviction from years of research, allowing an investor to withstand market volatility.

Fundamentally bearish view, with the speaker stating the company's drugs 'don't really work' and that it's an 'ugly duckling'. The investment is likely a trade rather than a long-term belief in fundamentals.

The speaker is very bullish, viewing the stock as significantly undervalued after a 'massive breakthrough' from the FDA. It is held as one of his largest long positions with expectations of significant appreciation.

The FDA lifted its clinical hold on the drug Elevidys, which is a massive de-risking event. The speaker believes the stock could reach $90 per share and suggests buying on dips under $21.

A high-risk, high-reward investment opportunity dependent on a future FDA decision regarding a drug with known liver toxicity. The speaker is bullish, viewing a potential small safety trial as a path to re-approval.

The sentiment is described as cautiously bullish, with a 'tiny tiny' 'shadow of hope', suggesting a potential for positive developments but with high uncertainty. The stock's +4% daily performance was also noted positively.

Considered a potential turnaround play for high-risk investors. After a massive price drop, the speaker believes 'all the bad news seems like it's baked in'.

The speaker has a bullish outlook, viewing the recent price drop due to FDA issues as a buying opportunity and believes the stock has a valuation floor around $20 per share.

A high-risk, speculative buy based on the valuation of its existing PMO drug franchise ($900M revenue), which is argued to be worth $20-$30/share alone. The potential return of its halted drug Elevitus is viewed as a free call option.

The market is undervaluing the company's potential $1.4 billion in high-margin revenue from its key drug franchises. The speaker believes it could be valued by private equity at at least five times sales.

The FDA's decision to keep Elevidys on the market with a black box warning is a major de-risking event that removes the primary overhang on the stock. This has created a bullish catalyst with potential for a short squeeze.

The speaker is bullish, stating 'I like Sarepta' and speculating that the stock may have hit its low point, making it a potentially attractive investment.

Listed as one of the biotech/pharma companies the speaker holds positive views on and/or has positions in.

A long position in the speaker's portfolio, but he advises caution by suggesting a smaller portfolio allocation of only 5-10%.

Speaker is long the stock and believes there is significant underlying value that may take time to be realized.

The speaker is long, calling it their biggest position. They believe the market is overly pessimistic about the risk of its key drug, Elevidys, being removed, creating a significant buying opportunity given strong revenue growth and a deep pipeline.

The speaker is extremely bearish, raising significant safety concerns about the company's gene therapy products, calling it a 'Piece of shit' and noting the stock price is stagnant.

The speaker is long the stock, viewing it as a 'good value play'. The investment is described as a 'slog', suggesting it is a long-term holding that requires patience and should be part of a diversified portfolio.

This is the speaker's biggest long position (10% of portfolio), held with high conviction for its long-term recovery potential despite recent poor stock performance.

The speaker is very bullish, holding a large 10% portfolio position. He believes the company's LGMD drug alone could be worth more than the entire current market cap.